Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppressant regimens in liver transplant for Hepatitis C
NCT00163657Phase 4Completed
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Jul 2002
- Primary completion
- Apr 2006
- Modality
- Small Molecules, Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of daclizumab, mycophenolate mofetil and cyclosporine in Allograft Rejection (AR) and hepatitis C (HCV) (3 arms), sponsored by Baylor Scott & White Research Institute. Primary endpoints: Freedom From Acute Rejection or HCV Recurrence or Treatment Failure at 12 months and Freedom From HCV Recurrence Within First Year That Requires HCV Antiviral Therapy and Freedom From Treatment Failure at 12 months. Started Jul 2002; status: completed.
02
Drugs
daclizumabmycophenolate mofetilcyclosporine
03
Conditions
Allograft Rejection (AR)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00163657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00163657.